Speaker: Amer Zeidan

0:56:25

Post #ASH24 Most Important MDS Studies

0:43:11

Post #ASH21 by the IACH: a focus on MDS

0:47:26

POST ASH22 MDS summary

1:00:07

The Therapeutic Revolution in management of Higher risk MDS: A focus on immunotherapy

1:05:39

Post ASCO/EHA 2023 Roundtable Discussion on the latest updates in MDS

0:02:43

Combining ziftomenib with chemotherapy for the treatment of AML: the KOMET trials

0:56:35

MedNews Week Keynote Conference (Live Stream) - Dr. Amer Zeidan (Yale Cancer Center)

0:02:39

The KOMET-007 trial: ziftomenib plus intensive chemotherapy to treat AML

0:00:36

Looking forward to the VJHemOnc post-ASH MDS highlights webinar

0:39:49

Imetelstat in patients with lower-risk MDS

0:01:52

Advances in LR-MDS and HR-MDS in 2023 and beyond

0:02:33

Immune checkpoint blockade upfront in older AML and HR-MDS

0:01:48

Immune Checkpoint Inhibition and Novel Therapies for Myelodysplastic Syndromes/Neoplasms

0:01:03

Exploring the safety & efficacy of magrolimab plus oral decitabine/cedazuridine in MDS

0:06:58

Next questions in AML

0:03:51

Venetoclax plus azacitidine in treatment-naïve and R/R MDS

0:03:08

Hypomethylating agents in AML

0:02:18

Phase Ib study of venetoclax plus azacitidine in patients with R/R MDS

0:03:35

Onvansertib with cytarabine or decitabine for R/R AML

0:02:00

Key MDS updates from the 2021 ASH meeting

0:01:34

Follow-up from the COMMANDS trial beyond the primary endpoint: luspatercept versus ESA-based therapy

0:02:32

MDS highlights from ASH 2024

0:08:31

Targeting BCL-2 in MDS

0:01:12

Phase I study of ziftomenib with venetoclax or venetoclax/azacitidine or 7+3 in R/R AML